Fertin Pharma completes cross-border acquisition of Tab Labs

2 minute read
07 January 2019

On Jan. 7, 2019, Fertin Pharma A/S announced that it had acquired Tab Labs Inc.

Fertin Pharma, headquartered in Vejle, Denmark, is the leading independent B2B developer and manufacturer of medicated chewing gum, primarily nicotine chewing gum used for withdrawal management in the process of tobacco cessation. Tab Labs is a full-service, private label contract manufacturer of functional tablets and chewing gum based in Vancouver, British Columbia.

Tab Labs will serve as an important bridgehead for Fertin Pharma in the large North American market for dietary supplement products delivered through innovative and convenient systems such as chewing gum, mints, lozenges and Zapliq®. Tab Labs will also provide MedCan Pharma A/S, an affiliate of Fertin Pharma, with an interesting opportunity to serve the Canadian market with edible types of Cannabinoid containing products.

Gowling WLG advised Fertin Pharma in this acquisition with a team that included Stefan McConnell (corporate/M&A), Paul Carenza (tax), Krista Schofer (employment) and Karoline Clarke (real estate), assisted by student-at-law Kean Silverthorn.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.